BPC-157
Tissue repair / recovery
Status & caution. Not FDA-approved for any human indication. Among the 12 peptide bulk substances FDA removed from the Category 2 'do-not-compound' list in April 2026 (after the nominations were withdrawn) and scheduled for Pharmacy Compounding Advisory Committee (PCAC) review on 23 July 2026. Removal from Category 2 does NOT by itself authorise compounding — that needs a favourable PCAC vote and formal FDA rulemaking. Selling it as a 'research chemical' for human use remains unlawful. The most-used healing peptide, but human trial data are essentially absent — popularity is not evidence. Almost all support is animal studies.
At a glance
Indications & what it's studied for
Reported for tendon/ligament/muscle healing, gut lining repair, and inflammation. Mechanisms proposed include angiogenesis and growth-factor modulation.
Contraindications & cautions
No established human contraindications because no human-use approval exists; caution with active malignancy given pro-angiogenic activity in animal models.
Commonly reported dosing
Reported, not recommended. The following describes what appears in research literature and community use. It is not a protocol, and unapproved peptides have no validated human dosing.
Community use commonly reports small daily subcutaneous doses, sometimes near the injury site, for short cycles; oral capsules are used for gut-specific goals. None of this is validated in humans.
Routes of administration
Subcutaneous injection; oral capsules (for GI targets).
Don't combine with
No well-characterised drug interactions; the bigger issue is unknown purity in grey-market vials.
Reported to stack with
Frequently combined with TB-500 (the 'Wolverine stack') for healing — two unapproved agents together.
Note: "stacking" combines multiple agents and multiplies unknowns; popularity of a combination is not evidence of its safety.
What the research actually shows
Extensive rodent literature on tendon, gut, and nerve healing; almost no controlled human trials, which is the central caveat.
Before acting on anything here, see Safety & the grey market and how to read a COA.